In this issue:
- Cell-free DNA blood-based test for CRC screening
- Next-generation multitarget stool DNA test for CRC screening
- National CRC screening is associated with stage shift to earlier diagnosis
- FIT and questionnaire-based risk assessment in CRC screening
- Pathological features and risk of metachronous CRC
- Treatment patterns in early- vs late-onset CRC
- Targeted agents for adjuvant therapy in mCRC surgical resection
- Total neoadjuvant therapy and chemoradiotherapy neoadjuvant treatment in rectal cancer
- Real-world safety and effectiveness of a bevacizumab biosimilar in mCRC
- First-line oxaliplatin-based chemotherapy + nivolumab for metastatic microsatellite- stable CRC
Please login below to download this issue (PDF)